Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas

Diabetic Medicine

Volumn 16, Issue 7, 1999, Pages 586-590

  Stahl, M ^a   Berger, W ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

Long and short acting sulphonylureas; Severe hypoglycaemia

Indexed keywords

GLIBENCLAMIDE; GLIBORNURIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOOD INTAKE; GERIATRIC PATIENT; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; INCIDENCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; EMERGENCIES; FEMALE; GLYBURIDE; HOSPITALS, UNIVERSITY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INPATIENTS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; SWITZERLAND;

EID: 0032756168     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00110.x     Document Type: Article

References (24)

1. 1 Lorenz N, Hillenbrand H. Wieviel Diabetiker gibtes in Deutschland? Diabetes J 1993; 11: 4-8.
2. 2 Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203-208.
3. 3 Malouf R, Brust JCM. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 1985; 17: 421-430.
4. 4 Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983; 24: 412-417.
5. 5 Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-183.
6. 6 Sugarman JR. Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diab Res Clin Prac 1991; 14: 139-48.
7. 7 Bachmann W, Löbe A, Lacher F. Medikamentös bedingte Hypoglykämien bei Typ-II-Diabetes. Diab Stoffw 1995; 4: 83-89.
8. 8 Berger W, Caduff F, Pasquel M, Rump A. Die relative Häufigkeit der schweren Sulfonylharnstoff-Hypoglykaemic in den letzten 25 Jahren in der Schweiz. Schweiz Med Wschr 1986; 116: 145-151.
9. 9 Nordic Council on Medicines. Nordic statistics on medicines. II. In Nordic Drug Index with Classification and Defined Daily Doses Uppsala: NI.N Publication no. 9, 1982.
10. 10 Dean AG, Dean JA, Burton AH, Dicker RC. Epi info, Version 5: a word processing, database and statistics system for epidemiology on microcomputers. Stone Mountain, Georgia: USD Inc. 1990.
11. 11 Dahlen M, Bergman U, Idman L, Martinsson I., Karlsson G. Epidemiology of hypoglycaemia in patients on oral antidiabetic drugs in the island of Gotland, Sweden. Acta Endocrinol (Copenh) 1984; 106 Suppl 263: A 21.
12. 12 Taylor JA. Pharmacokinetics and biotransformation of chlorpropamide in man. Clin Pharmacol Ther 1972; 13: 710-718.
13. 13 Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-1245.
14. 14 Balant I., Zahnd GR, Weher F, Fabre J. Behavior of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 1977; 11: 19-25.
15. 15 Jaber I.A, Antal F.J, Slaughter RL, Welshman IR. Comparison of pharmacokinetics and pharmacodynamics of short-and long-term glyburide therapy in NIDDM. Diabetes Care 1994; 17: 1300-1306.
16. 16 Hellman B, Sehlin J, Täljedal IB. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in β-cell-rich pancreatic islets. Acta Endocr 1984; 105: 385-390.
17. 17 Behrle M. Untersuchung zur Pharmakokinetik von Glibenclamid bei Nierengesunden und Niereninsuffizienten Diabetikern. PhD Thesis, Heidelberg: Ruprecht-Karl-Universität, 1980.
18. 18 Jönsson A, Rydberg T, Ekberg G, Hallegren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145.
19. 19 Van Staa T, Abenhaim I., Monette J. Rates of hypoglycaemia in users of sulphonylureas. J Clin Epidemiol 1997; 50: 735-741.
20. 20 Michaelis D, Jutzi E. Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR: Alters-und geschlechts-spezifische Inzidenz-und Právalenztrends im Zeitraum 1960-1987. Z Klin Med 1991; 46: 59-64.
21. 21 Rett K, Lotz N, Wickelmayr M, Fink E, Jausch KW, Gunther B et al. Verbesserre Insulinwirkung durch ACE-Hemmung beim Typ-II-Diabetiker. Dtsch Med Wochenschr 1988; 113: 243-249.
22. 22 Yang Yj Hope ID, Ader M, Bergman RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 1989; 84: 1620-1628.
23. 23 Pollare T, Lithell H, Berne CA. A comparsion of the effects of hydrochlorothiazide and capropril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
24. 24 Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-737.